Cole Steven A, Saleem Rehan, Shea William P, Sedler Mark, Sablosky Marilyn, Jyringi Darlene, Smith Angela
SUNY Stony Brook Health Sciences Center, New York 11794-8101, USA.
Int J Psychiatry Med. 2005;35(1):91-8. doi: 10.2190/NAMG-XXGG-WDVY-GX04.
These case reports examine the potential efficacy and safety of ziprasidone for the treatment of agitation or psychosis in dementia.
The authors performed a retrospective chart review of three patients with DSM-IV diagnoses of dementia, treated with ziprasidone for agitation/psychosis on an academic psychiatric inpatient unit in 2002-2003. In addition, these three case reports are supplemented by a clinical report of the first outpatient with DSM-IV diagnosis of dementia completing a prospective open-label six-week study in 2004 evaluating the use of oral ziprasidone for agitation/psychosis in dementia. Qualitative descriptions of clinical improvement provide outcome data for these case reports.
Four patients with dementia with agitation/psychosis experienced marked behavioral improvement after receiving oral doses of ziprasidone (20-160 mg/day), without any evidence of problematic cardiac or other side-effects. Two of the four patients had final EKGs and both of these patients demonstrated no change of QTc interval after administration of ziprasidone.
These case reports suggest that oral ziprasidone may be an effective and safe medication for the treatment of agitation or psychosis in patients with dementia.
这些病例报告探讨了齐拉西酮治疗痴呆患者激越或精神病性症状的潜在疗效和安全性。
作者对2002年至2003年在一家学术性精神科住院部接受齐拉西酮治疗激越/精神病性症状的3例符合DSM-IV痴呆诊断标准的患者进行了回顾性病历审查。此外，这3例病例报告还补充了1例2004年完成前瞻性开放标签六周研究的门诊患者的临床报告，该患者符合DSM-IV痴呆诊断标准，评估口服齐拉西酮治疗痴呆患者激越/精神病性症状的情况。临床改善的定性描述为这些病例报告提供了结果数据。
4例伴有激越/精神病性症状的痴呆患者在口服齐拉西酮（20 - 160毫克/天）后行为有显著改善，且无任何心脏问题或其他副作用的证据。4例患者中有2例进行了最终心电图检查，这2例患者在服用齐拉西酮后QTc间期均无变化。
这些病例报告表明，口服齐拉西酮可能是治疗痴呆患者激越或精神病性症状的一种有效且安全的药物。
